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Capsiate Inhibits DNFB-Induced Atopic Dermatitis in
NC/Nga Mice through Mast Cell and CD4+ T-Cell
Inactivation
Ji H. Lee1,2, Yun S. Lee1,2, Eun-Jung Lee1, Ji H. Lee1 and Tae-Yoon Kim1
Capsaicin has many biological effects, such as antioxidant, anticancer, and antiangiogenic effects, but it is rarely
used because of its high pungency. Capsiate, a nonpungent capsaicin analog, also has multiple biological effects,
similar to those of capsaicin, but does not cause irritation. However, the effect of capsiate on allergic responses
and immune cells has not been well studied. In this study, we investigated the effect of capsiate on atopic
dermatitis, mouse CD4+ T cells, and mast cell activation. Capsiate inhibited DNFB-induced atopic dermatitis in
NC/Nga mice. Topical treatment with capsiate suppressed serum IgE levels and cytokine and chemokine
expression in the skin of DNFB-treated NC/Nga mice. In addition, it suppressed the activation of CD4+ T cells
and mast cells, which are implicated in allergic diseases. Capsiate inhibited the differentiation of naïve CD4+
T cells into T helper type 1 (Th1), Th2, and Th17 cells. Treatment with capsiate inhibited the expression of
pro-inﬂammatory cytokines and degranulation from activated bone marrow–derived mast cells through the
inhibition of extracellular signal–regulated kinase signal pathways. Consistent with these results, treatment with
capsiate inhibited passive cutaneous anaphylaxis. Taken together, our results suggest that capsiate might be a
good candidate molecule for the treatment of allergic diseases such as atopic dermatitis.
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INTRODUCTION
Capsaicin exhibits antioxidant, anticancer, and antiangio-
genic activity (Murakami et al., 2001; Min et al., 2004).
Despite these beneﬁcial effects, capsaicin is rarely considered
for use as an antioxidant or anticancer drug because of its
high pungency that leads to irritation. However, capsiate (4-
hydroxy-3-methoxybenzyl (E)-8-methyl-6-nonenoate), isolated
from the fruit of a cultivar of Capsicum annuum L.(CH-19
Sweet; Sundelin et al., 2005), is a nonpungent capsaicin
analog with an ester bond instead of the amide bond between
the vanillyl moiety and the fatty acid chain. Importantly,
capsiate has multiple biological effects without causing
irritation, including an anti-inﬂammatory effect (Lee et al.,
2010). Treatment with capsiate inhibits the expression of
UV-induced pro-inﬂammatory mediators in keratinocytes.
Furthermore, topical treatment with capsiate inhibits UVB-
induced cyclooxyganase-2 and pro-inﬂammatory cytokine
expression in mouse dorsal skin. Capsiate also has an
antiangiogenic effect (Pyun et al., 2008; Lee et al., 2010).
Topical treatment with capsiate inhibits the expression of
UVB-induced pro-angiogenic factors (Lee et al., 2010) and
blocks tumor-induced and vascular endothelial growth factor-
induced angiogenesis (Pyun et al., 2008).
Immune cells are highly involved in inﬂammation. How-
ever, the effects of capsiate on T cells, mast cells, and allergic
responses, which are important in the development of allergic
inﬂammation, have not been well studied. Atopic dermatitis
(AD) and asthma are allergic diseases that are induced by
activated T helper type 2 (Th2) cells and mast cells. Mast cells
are activated by the binding of allergen-bound IgE to the FcεRI
(Rivera, 2002; Kalesnikoff and Galli, 2008); subsequently,
activated mast cells release many biologically active pro-
ducts, such as pre-stored mediators, including histamine, and
newly synthesized mediators, including cytokines (IL-4, IL-5,
and IL-13, and tumor necrosis factor-α) and arachidonic acid
metabolites (leukotrienes and prostaglandins; Theoharides
et al., 2007). These released mediators cause allergic inﬂam-
matory diseases such as asthma. Thus, the inhibition of mast
cell activation or mediators from activated mast cells is the
main method for treating or preventing allergic diseases
(Rivera and Gilﬁllan, 2006; Kraft and Kinet, 2007).
CD4+ T cells are also key factors in allergic inﬂammatory
diseases. Th2 cells produce IL-4, which induces B-cell
activation and class switching to IgE; increased IL-4 produc-
tion or induction of the IL-4 signaling pathway causes allergic
diseases (Hershey et al., 1997). Recently, it was also reported
that IL-17, which is produced by Th17 cells, is implicated in
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asthma. The messenger RNA and protein levels of IL-17 are
increased in the lungs, sputum, bronchoalveolar lavage ﬂuids,
and sera of asthmatic patients (Molet et al., 2001; Wong et al.,
2001; Chakir et al., 2003; Bullens et al., 2006). Furthermore,
Th17 cells are involved in the pathogenesis of AD (Koga et al.,
2008). The percentage of Th17 cells was increased in
peripheral blood of AD patients, and the severity of AD
was also associated with the Th17 cell percentage. Therefore,
it seems that IL-17 and Th17 cells are involved not only in
autoimmune diseases such as rheumatoid arthritis and
psoriasis (Hirota et al., 2007; Lowes et al., 2008) but also in
the development of various allergic diseases.
NC/Nga mice are normal when they are kept in pathogen-
free conditions. However, repeated treatment with DNFB in
the shaved skin of NC/Nga mice induces symptoms of AD-
like skin inﬂammation, such as increased epidermal thick-
ness, enhanced chemokine expression, high levels of serum
IgE, and upregulation of Th2 cytokines (Tomimori et al., 2005;
Jin et al., 2009; Kim et al., 2011). Thus, DNFB-induced AD is
a well-known mouse model of AD.
In the present study, we investigated the anti-allergic effect
of capsiate using DNFB-induced AD-like skin inﬂammation in
NC/Nga mice. Our results show that capsiate inhibited DNFB-
induced AD-like skin inﬂammation in NC/Nga mice. In
addition, capsiate was also shown to inhibit passive cutan-
eous anaphylaxis (PCA) in mice. Furthermore, we demon-
strated the inhibitory effect of capsiate on mast cell activation
as well as on CD4+ T-cell activation and differentiation,
suggesting that the anti-allergic effect of capsiate might result
from the inhibition of mast cell and CD4+ T-cell activation.
RESULTS
Treatment with capsiate inhibited DNFB-induced AD-like skin
inﬂammation in Nc/Nga mice
To determine whether capsiate could inhibit AD in mice, we
induced AD-like skin inﬂammation with DNFB with or
without capsiate treatment (Figure 1a). Figure 1b shows that
treatment with capsiate suppressed DNFB-induced AD-like
skin inﬂammation. A histological examination also showed
that epidermal thickness was reduced upon treatment
with capsiate (Figures 1c and d). In addition, the number of
mast cells and CD4+ T cells in the skin also decreased after
treatment with capsiate (Figure 1e; Supplementary Figure S1
online). Eosinophil inﬁltration is also involved in AD
pathogenesis, and thus the eosinophil number in mouse skin
was determined. Figure 1f shows that the eosinophil number
reduced in mouse skin treated with capsiate.
One of the major characteristics of AD is the increased
level of serum IgE. Thus, we determined the level of serum IgE
using an ELISA. DNFB-treated Nc/Nga mice showed
increased IgE levels. However, capsiate-treated Nc/Nga mice
showed decreased serum IgE levels, suggesting that capsiate
could inhibit AD (Figure 2a). It is also known that the
expression levels of cytokines, such as IL-4 and thymic
stromal lymphopoietin (TSLP), are increased in AD skin
(Homey et al., 2006). Therefore, we determined the levels of
IL-4 and TSLP in mouse skin using a real-time PCR
experiment. Figure 2b shows that the gene expression levels
of IL-4 and TSLP increased in DNFB-treated mouse skin but
decreased in capsiate-treated skin (Figure 2b).
Increased chemokine expression is also a characteristic of
AD skin lesions because chemokines recruit immune
cells, including CD4+ T cells, into skin lesions. Thus, we
investigated the expression levels of CCL11, CCL17, and
CCL22 genes in mouse skin and found that treatment with
capsiate suppressed these gene expression levels, which were
elevated in the mouse skin with DNFB-induced AD-like skin
inﬂammation (Figure 2c). These results conﬁrmed that
capsiate could inhibit DNFB-induced skin inﬂammation.
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Figure 1. Treatment with capsiate inhibits DNFB-induced AD-like skin
inﬂammation in NC/Nga mice. (a) Experimental scheme for the DNFB-
induced AD model. (b) The photographs were taken on day 28. (c) Histology of
back skin. Sections recovered from negative control, DNFB-treated (positive
control), and DNFB- and capsiate-treated mice were stained with hematoxylin
and eosin. Scale bar=100 μm. (d) The epidermal thickness of the back skin in
DNFB-/capsiate-treated mice was less than that in DNFB-treated positive
control mice. The epidermal thickness of capsiate only–treated mouse skin did
not increase. Data represent mean± SE. (e) Percentages of mast cells (FcεRI+
and CD117+) and CD4+ T cells in skins were determined by ﬂow cytometry
after single cell suspension and staining with ﬂuorescence tagged antibodies.
(f) Eosinophils were counted in ﬁve high-power ﬁelds (HPF). Data represent
mean± SE. Data are from three independent experiments, with four mice per
group. *Po0.05. AD, atopic dermatitis.
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As it is well known that Th2 cells are implicated in allergic
disorders, we determined the percentages of Th2 cells,
secreting IL-4 or IL-5, in draining lymph nodes. Figure 3
shows that when AD-like skin inﬂammation was induced by
DNFB, the percentages of IL-4-expressing CD4+ T cells and
IL-5-expressing CD4+ T cells in draining lymph nodes
increased to 12.38% and 6.00%, respectively, whereas in
the lymph nodes of normal NC/Nga mice 2.57% of the CD4+
T cells expressed IL-4 and 0.26% expressed IL-5. On the other
hand, capsiate-treated mice showed decreased percentages of
IL-4- and IL-5-expressing CD4+ T cells (3.94% and 1.15%,
respectively) compared with positive control mice.
Recently, it was reported that Th17 cells are also involved
in the pathogenesis of AD (Koga et al., 2008). Thus, we
determined the percentages of Th17 cells and Th1 cells.
Levels of Th17 cells were increased in DNFB-treated mice
(6.40%) but Th1 cell levels were only slightly increased
(3.07%). Furthermore, capsiate inhibited Th17 cell differen-
tiation in draining lymph nodes of DNFB-treated mice
(Figure 3). These results imply that DNFB-induced AD-like
skin inﬂammation may be caused at least by Th2 and Th17
cells, and that capsiate inhibits the AD-like skin inﬂammation
through suppression of Th2 and Th17 cell differentiation. To
determine the effect of capsiate itself in unstimulated NC/Nga
mice, capsiate was used for treatment without DNFB
stimulation. The results showed that capsiate does not have
an effect on unstimulated NC/Nga mice.
Capsiate inhibits mast cell activation
Mast cells are one of the major cell types involved in an
allergic response. However, there are no reports on the effects
of capsiate on mast cells or the allergic response. To
determine the effect of capsiate on mast cell activation, we
generated bone marrow–derived mast cells (BMMCs) from
mice, as described in the Materials and Methods section
(Figure 4a). Activated mast cells express and produce pro-
inﬂammatory cytokines such as IL-1β, IL-6, IL-17, and tumor
necrosis factor-α. Therefore, we determined the levels of pro-
inﬂammatory cytokines in activated BMMCs that were
pretreated or not with capsiate. The results showed that
pretreatment with capsiate inhibited pro-inﬂammatory cyto-
kine expression without cytotoxicity (Figure 4b; Supple-
mentary Figure S2A online).
TRPV1 is the receptor of capsiate. Therefore, we deter-
mined whether the knockdown expression of TRPV1 in mast
cells abrogates the inhibitory effect of capsiate. The inhibitory
effect of capsiate was only partially suppressed after transfec-
tion of TRPV1 small interfering RNA, probably because
transcripts of TRPV1 were not perfectly knocked down or
another receptor might be involved in the inhibitory effect of
capsiate on mast cell activation (Supplementary Figures S3A
and B online).
Capsiate inhibits the extracellular signal–related kinase signal
pathway in activated BMMCs
Many signal pathways, such as Syk, PI3K, Akt, and
extracellular signal–regulated kinase (ERK), are involved
in mast cell activation. To determine which signal
pathways are inhibited by capsiate in activated mast
cells, BMMCs were activated by dinitrophenol (DNP)-IgE
and DNP-human serum albumin (HSA), and treated
with or not treated with capsiate. The activated mast cells
were collected and stained for pSyk, pAkt, and pERK,
followed by ﬂow cytometry and FACS analysis. Figure 4c
shows that treatment with capsiate inhibited the phos-
phorylation of ERK in the BMMCs (from 29.05 to 14.09%).
The mean ﬂuorescence intensity also decreased after treat-
ment with capsiate (from 11.07 to 7.68). The results were
conﬁrmed by western blot analysis (Figure 4d). The phos-
phorylations of Syk and Akt were not affected by capsiate
(data not shown). Therefore, the inhibition of mast cell
activation by capsiate may be the result of suppressed ERK
signal pathways.
Capsiate inhibits PCA in mice
We expect that capsiate has an anti-allergic effect in vivo
because it inhibits mast cell activation. To determine whether
capsiate inhibits allergic responses, we induced DNP-speciﬁc
IgE-mediated PCA in mice. Mice were sensitized by the
intradermal injection of DNP-IgE (100 ng per ear). The next
day, capsiate was administrated 1 hour before intravenous
injection of DNP-HSA (100 μg μl− 1) containing 4% Evan’s
blue (Figure 5a). Figure 5b shows that topical treatment with
capsiate decreased the activated mast cell–mediated leakage
of blood vessels, resulting in a decrease in the amount of
diffused dye. Measurement of the extracted dye intensity
showed that treatment with capsiate reduced dye intensity by
62.5%, compared with the untreated positive control group
(Figure 5c). The increased ear thickness was also abrogated,
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Figure 2. Treatment with capsiate causes decreased levels of serum IgE,
cytokine expression, and chemokine expression. (a) Serum IgE level was
measured using ELISA as described in the Materials and Methods section.
Expression levels of (b) cytokines and (c) chemokines in AD-induced NC/Nga
mouse skin were determined by real-time PCR. Data represent mean± SE. A
representative example of three independent experiments is shown. *Po0.05.
AD, atopic dermatitis; TSLP, thymic stromal lymphopoietin.
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from 10.7 to 4.2 μm (Figure 5d). These results suggest that
capsiate has an anti-allergic effect through the inhibition of
mast cell activation.
Capsiate inhibits CD4+ T-cell proliferation and differentiation
To investigate the role of capsiate on CD4+ T cells, a H3
incorporation assay was performed. The results showed that
treatment with capsiate (>25 μM) inhibited anti-CD3/anti-
CD28 antibody-stimulated CD4+ T-cell proliferation
(Figure 6a). Furthermore, an ELISA experiment also showed
that the level of IL-2 in anti-CD3/anti-CD28 antibody–
stimulated CD4+ T-cell culture supernatant decreased when
425 μM capsiate was applied (Figure 6c).
To conﬁrm the inhibitory activity of capsiate on CD4+
T-cell proliferation, we carried out a carboxyﬂuorescein
succinimidyl ester (CFSE) dilution assay. Figure 6b shows that
treatment with capsiate inhibited CD4+ T-cell proliferation,
which is consistent with the results of the H 3 incorporation
assay. Previously, we reported that capsiate could inhibit Lck
signaling in activated CD4+ T cells (Lee et al., 2010). Thus,
the inhibitory effect of capsiate on CD4+ T-cell proliferation
might result from the suppression of the Lck signaling
pathway.
CD4+ T cells are implicated in the pathogenesis of atopic
dermatitis (Grewe et al., 1998). Therefore, we determined
whether capsiate could inhibit CD4+ T-cell differentiation.
Naive CD4+ T cells were isolated from mouse spleen
and lymph nodes as described in the Materials and Methods
section, and cultured under Th1, Th2, and Th17
differentiation conditions. After 4 days in culture, the CD4+
T cells and culture supernatants were collected for real-time
PCR and ELISA experiments, respectively. Real-time PCR
results showed that treatment with 25 μM capsiate inhibited
the expression of transcription factors, T-bet, GATA-3, and
RORγT, which are necessary for Th1, Th2, and Th17
differentiation, respectively. In addition, the expression levels
of the signature cytokines of Th1, Th2, and Th17 cells (IFN-γ,
IL-4, and IL-17, respectively) were also inhibited when naive
Negative
CTL
IL
-5
IL
-4
IF
N
-g
am
m
a
IL
-1
7A
CD4
1.70 2.31 6.40 3.18
2.183.070.910.64
2.57
0.26
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
10
4
103
10
3
102
10
2
101
10
1
100
10
0
10
4
10
3
10
2
10
1
10
0
10
4
10
3
10
2
10
1
10
0
10
4
10
3
10
2
10
1
10
0
0.91 6.00 1.15
3.30 12.38 3.94
Capsiate DNFB
DNFB+
capsiate
Figure 3. Treatment with capsiate inhibits Th2 and Th17 cell differentiation in draining lymph nodes of AD-induced NC/Nga mice. Development of Th2, Th17,
and Th1 cells in draining lymph nodes was determined by intracellular staining and FACS analysis. A representative example of three independent experiments is
shown. AD, atopic dermatitis; CTL, control.
JH Lee et al.
Capsiate Inhibits Atopic Dermatitis in Mice
1980 Journal of Investigative Dermatology (2015), Volume 135
CD4+ T cells were cultured under Th1, Th2, and Th17
conditions, respectively, with capsiate (Figures 6e, g, and h).
Consistently, ELISA showed that the released IL-17 and IFN-γ
levels decreased upon capsiate treatment when naive CD4+
T cells were cultured under Th17 and Th1 conditions (Figures
6d and f). Interestingly, capsiate did not affect regulatory
T-cell differentiation (Figures 6i and j). We also showed that
capsiate is not cytotoxic in CD4+ T cells (Supplementary
Figure S2B online). Thus, these results suggest that capsiate
might inhibit CD4+ T-cell–mediated diseases because of its
inhibitory activity against CD4+ T-cell proliferation and
differentiation.
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DISCUSSION
Capsaicin exhibits antioxidant, anticancer, and antiangio-
genic effects (Murakami et al., 2001; Min et al., 2004).
However, capsaicin has not been used as a drug because of
its high pungency that leads to irritation. Capsiate, a
nonpungent capsaicin analog, has similar biological
effects to those of capsaicin without causing irritation. It has
anti-inﬂammatory and antiangiogenic effects (Pyun et al.,
2008; Lee et al, 2010). Both capsaicin and capsiate
have been reported to have inhibitory effects on T cells.
Capsaicin inhibits Jurkat T-cell activation (Fischer et al., 2001)
and capsiate inhibits T-cell and NF-κB activation (Sancho
et al., 2002). However, the effects of capsiate on immune cells
have not been well studied. In this study, we demonstrated
the effects of capsiate on CD4+ T cells and mast cells. Our
results show that capsiate could inhibit CD4+ T-cell
proliferation. This result suggests that capsiate could be used
as an immunosuppressive agent similar to cyclosporine to
inhibit immune cell–mediated diseases, although more
detailed experiments are needed to conﬁrm this hypothesis.
Our results also showed that treatment with capsiate
inhibited Th1, Th2, and Th17 cell differentiation, probably
via the inhibition of CD4+ T-cell activation. CD4+ T-cell
subsets are involved in the pathogenesis of many diseases. For
example, Th17 cells are involved in the pathogenesis of
autoimmune diseases, including rheumatoid arthritis (Hirota
et al., 2007), psoriasis (Lowes et al., 2008), multiple sclerosis
(Tzartos et al., 2008), and uveitis (Amadi-Obi et al., 2007). On
the other hand, Th2 cells have been implicated in the
pathogenesis of allergic diseases, such as asthma (Ngoc et al.,
2005). Therefore, it would be worthwhile to investigate
whether capsiate can inhibit CD4+ T-cell–mediated
diseases, speciﬁcally autoimmune and/or allergic diseases.
We also demonstrated that capsiate inhibits mast cell
activation. Mast cells are critical for the induction of allergic
diseases, such as asthma, allergic rhinitis, and atopic
dermatitis. Mast cells are localized in many tissues, and
activation of mast cells induces the release of histamine,
tryptase, and pro-inﬂammatory cytokines, resulting in allergic
responses in many tissues. We have demonstrated that treat-
ment of mouse BMMCs with capsiate inhibited IgE-mediated
BMMC activation, resulting in the suppression of pro-
inﬂammatory cytokine expression in activated mouse
BMMCs. In addition, capsiate inhibited PCA in the mouse
ear, suggesting that capsiate has an anti-allergic effect.
Recently, it was reported that capsaicin treatment reduces
nasal hyper-reactivity in patients with idiopathic rhinitis
(Van Gerven et al., 2014). The result is consistent with ours,
which shows that treatment with capsiate ameliorated DNFB-
induced AD-like skin inﬂammation in NC/Nga mice. Capsiate
is an analog of capsaicin and shares many biological
functions with it. Therefore, it seems that capsiate might be
useful in treating not only AD but also other allergic diseases.
Interestingly, it was also reported that IL-17 is involved in
airway hypersensitivity in asthmatic patients (Molet et al.,
2001; Barczyk et al., 2003). Our experimental results show
that capsiate has an anti-proliferative effect on CD4+ T cells,
an inhibitory effect on CD4+ T-cell differentiation including
Th17 cell differentiation, and anti-allergic effects. Therefore, it
will be interesting to determine whether capsiate could inhibit
airway hypersensitivity by the double inhibition of Th17 cells
and mast cells.
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Figure 5. Capsiate inhibits passive cutaneous anaphylaxis (PCA) in mice. (a) Experimental scheme for the PCA experiment. Mice were passively sensitized with
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Taken together, we demonstrated that capsiate could
regulate AD probably through the inactivation of Th2 cells
and mast cells. These results imply that capsiate might be a
good candidate molecule for the treatment of allergic diseases.
MATERIALS AND METHODS
Mice
C57BL/6 mice were obtained from the Korean Research Institute of
Biotechnology (Daejeon, Korea). All experiments with the mice were
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Figure 6. Capsiate inhibits CD4+ T-cell proliferation and differentiation. CD4+ T-cell proliferation was determined by (a) a H3 incorporation assay and (b) a
CFSE dilution assay. (c) The IL-2 levels released from activated CD4+ T cells were also determined by ELISA. Puriﬁed mouse CD4+ T cells were cultured under
Th1, Th2, Th17, or regulatory T cell (Treg) conditions for 4 days. Supernatants were collected for an ELISA experiment to quantify (d) IL-17, (f) IFN-γ, and (i) IL-10
levels. Total RNA was isolated from CD4+ T cells after Th1, Th2, Th17, or Treg differentiation. The mRNA levels of (e) IL-17 and RORγT for Th17 cell
differentiation, (g) IFN-γ and T-bet for Th1 cell differentiation, and (h) IL-4 and GATA-3 for Th2 cell differentiation, and (j) IL-10 and Foxp3 for Treg differentiation
were determined using real-time PCR. mGAPDH levels were used as an internal control. Data represent mean± SE. The results are representative of four
independent experiments. CFSE, carboxyﬂuorescein succinimidyl ester; CPM, counts per minute; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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approved by the Review Board of Experimental Animals Study
Committee at the Catholic University and performed following the
guidelines provided by the Committee.
Reagents
Roswell’s Park Memorial Institute 1,640 was purchased from Gibco
BRL (Grand Island, NY). Fetal bovine serum was purchased from
Hyclone (Logan, UT). DNP-speciﬁc monoclonal IgE, DNP-HSA, and
Evans blue were purchased from Sigma Chemical (St Louis, MO). The
antibody against the phosphorylated forms of ERK was purchased
from BD Biosciences (Franklin Lakes, NJ).
Cell culture
HMC-1 cells were grown in DMEM supplemented with 100 Uml− 1
penicillin, 100 μgml−1 streptomycin, and 10% heat-inactivated fetal
bovine serum at 37 °C under a humidiﬁed atmosphere containing 5%
CO2.
DNFB-induced AD
AD was induced in Nc/Nga mice by treatment with DNFB as
described previously (Tomimori et al., 2005; Jin et al., 2009; Kim
et al., 2011). We induced AD-like skin inﬂammation in mice with
minor modiﬁcation. Brieﬂy, AD was induced by sensitization with
topical application of 100 μl of 0.15% DNFB in acetone/olive oil
(3:1) to the shaved back skin on days 0 and 4, and challenge with
0.2% DNFB on days 8, 12, 16, 20, and 24. On day 28 the mice were
killed for analysis.
CD4+ T-cell isolation
Mouse CD4+ T cells were isolated as previously described (Lee et al.,
2011). Brieﬂy, C57BL/6 mouse lymph nodes and spleens were
collected and ground into a single cell suspension. Using the T-cell
enrichment columns and CD4+ MicroBeads (Miltenyi Biotec,
Bergisch-Gladbach, Germany), CD4+ T cells were isolated. The
purity of CD4+ T cells was > 95%.
Generation of mouse bone marrow–derived mast cells (BMMCs)
BMMCs were generated as previously described, with minor
modiﬁcations (Frossi et al., 2007; Lee et al., 2014). Brieﬂy, bone
marrow cells were obtained from tibias and femurs of 8–12-week-old
C57BL/6 mice. Lineage-negative cells were isolated from the bone
marrow cells using the lineage-negative cell isolation kit (Miltenyl
Biotech, Germany) according to the manufacturer’s instructions. The
lineage-negative cells were then cultured in Roswell’s Park Memorial
Institute 1,640 medium supplemented with 10% FCS, 100 Uml− 1
penicillin, 100 μgml− 1 streptomycin, nonessential amino acids, and
sodium pyruvate in the presence of mIL-3 (10 ngml−1) and mouse
stem cell factor (50 ngml− 1) for 7 weeks at 37 °C in a humidiﬁed
atmosphere with 5% CO2. FACS analysis showed that 497% of the
cells were positive for CD117 (c-Kit) and FcεRI.
3H-thymidine incorporation assay
The 3H incorporation assay was performed as previously described
(Yu et al., 2012). Brieﬂy, naive CD4+ T cells were isolated and
activated with an anti-CD3/anti-CD28 antibody (BD Biosciences) for
3 days. The cells were pulsed with 3H-thymidine (0.5 μCi/10 μl per
well) for 12 additional hours and analyzed. The 3H-thymidine
incorporation assay data are mean counts per minute± SE of ﬁve
replicate cultures.
Flow cytometry and intracellular cytokine analysis
Draining lymph nodes were isolated from mice and the lymph nodes
were ground for single cell suspension. The cells were activated
using anti-CD3 and anti-CD28 antibodies for 3 days and stained
with anti-IL-4, anti-IL-5, anti-IL-17 A, and IFN-γ antibodies (BD
Pharmingen, San Jose, CA) using a Cytoﬁx/Cytoperm kit (BD
Biosciences) as per the manufacturer’s protocol. Flow cytometry
was performed on a FACSCalibur (BD Bioscience).
CFSE dilution assay
The CFSE dilution assay was performed using the CellTrace CFSE Cell
Proliferation Kit (Molecular Probes, Eugene, OR) as described
previously (Lee et al., 2013). Brieﬂy, naive CD4+ T cells were
isolated and stained with CFSE at 37 °C for 10min. After quenching
the staining by the addition of ice-cold culture media, cells were
incubated for 5 minutes on ice and then collected and washed. The
cells were activated with anti-CD3/anti-CD28 antibody (BD Bios-
ciences) for 4 days and analyzed by ﬂow cytometry. The histogram
data showing each cell division were obtained using Cell Quest
Software (Becton Dickinson, Mountain View, CA).
RNA isolation, complementary DNA synthesis, and real-time
PCR
Total RNA was isolated from CD4+ T cells and BMMCs using the
TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions. First-strand complementary DNA was synthe-
sized from 1 μg total RNA using a reverse transcription system
(Qiagen, Hilden, Germany). The primer sets for IL-1β, IL-6, IL-17,
IFN-γ, and glyceraldehyde-3-phosphate dehydrogenase were pur-
chased (Qiagen). Glyceraldehyde-3-phosphate dehydrogenase mes-
senger RNA was used as an endogenous control. Real-time PCR was
performed using the Rotor-Gene 6000 (Corbett, New South Wales,
Australia) and a QuantiTect SYBR Green PCR kit (Qiagen). The
ampliﬁcation program consisted of 1 cycle of 95 °C for 10 minutes,
followed by 45 cycles of 95 °C for 20 seconds, 55 °C for 20 seconds,
and 72 °C for 20 seconds.
ELISA
For the detection of cytokines, BMMCs were sensitized with 1 μg/ml
DNP-IgE overnight. After washing the cells with phosphate-buffered
saline, the cells were treated with capsiate for 30 minutes and then
activated with 10 ngml−1 DNP-HSA for 24 hours. The supernatants
were collected and ELISA was performed as previously described
(Hur et al., 2010).
PCA in mice
An anti-DNP-speciﬁc IgE (100 ng per ear) was intradermally injected
into the mouse ear, followed 24 hours later by topical treatment with
capsiate (1 mM per ear). One hour later, the mice were challenged
with an intravenous injection of antigen (DNP-HSA; 500 μg) in 100 μl
phosphate-buffered saline containing 4% Evans blue. One hour after
antigen challenge, the mice were killed and the ears removed to
measure the amount of dye extravasated by the antigen. The dye was
extracted overnight from the ear in 800 μl formamide at 65 °C. The
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intensity of the absorbance was measured at 620 nm (n= 5 mice in
each group).
Statistical analyses
Statistical comparisons between groups were made using unpaired
two-sided t-tests and differences with Po0.05 (*) and Po0.005 (**)
were considered signiﬁcant. All experiments were performed at least
three times.
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